{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01730547",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MSC-MS"
      },
      "Organization": {
        "OrgFullName": "Karolinska Institutet",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stem Cells for Multiple Sclerosis",
      "OfficialTitle": "Phase 1/2 Clinical Trial With Autologous Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2015",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "February 2013"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2015",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2015",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "November 9, 2012",
      "StudyFirstSubmitQCDate": "November 20, 2012",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "November 21, 2012",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "January 14, 2015",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 15, 2015",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Ellen Iacobaeus",
        "ResponsiblePartyInvestigatorTitle": "MD.PhD",
        "ResponsiblePartyInvestigatorAffiliation": "Karolinska Institutet"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Karolinska Institutet",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The aim of the study is to evaluate the safety and efficacy of autologous mesenchymal stromal cells as treatment for Multiple Sclerosis."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Multiple Sclerosis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Mesenchymal stem cells",
          "Multiple Sclerosis",
          "Autoimmune diseases"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Crossover Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Quadruple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "15",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Early treatment with mesenchymal stem cells",
            "ArmGroupType": "Active Comparator",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Autologous mesenchymal stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Delayed treatment with mesenchymal stem cells",
            "ArmGroupType": "Active Comparator",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Autologous mesenchymal stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Autologous mesenchymal stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Delayed treatment with mesenchymal stem cells",
                "Early treatment with mesenchymal stem cells"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "To assess the safety of IV therapy with autologous Mesenchymal Stem Cells (MSCs) in MS patients.",
            "PrimaryOutcomeDescription": "The primary objective of the study is to assess the safety of IV therapy with autologous MSCs in MS. Number of participants with adverse events will be documented at week 0,4,8,12,16,20,24,28,32,36,40,44,48 post treatment. Co-primary objective of the study is to evaluate the activity of autologous MSCS in MS patients, in terms of reduction as compared to placebo in the total number of contrast-enhancing lesions (GEL) at MRI acquired on conventional 1,5 T MRI scans over 24 weeks.",
            "PrimaryOutcomeTimeFrame": "48 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "To gather preliminary information of the efficacy of the experimental treatment in terms of combined MRI activity and clinical efficacy (incidence of relapses and disability progression).",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nDiagnosis of MS\n\na. Relapsing remitting MS (RRMS) not responding to at least a year of attempted therapy with one or more of the approved therapies (beta-interferon, glatiramer acetate, natalizumab, mitoxantrone, fingolimod) as evidenced by one or more of the following: i. ≥1 clinically documented relapse in past 12 months ii. ≥2 clinically documented relapses in last 24 months iii. ≥1 GEL at MRI performed within the last 12 months\n\nb. Secondary progressive MS (SPMS) not responding to at least a year of attempted therapy with one or more of the approved therapies (beta-interferon, glatiramer acetate, natalizumab, mitoxantrone, fingolimod) as evidenced by both: i. an increase of ≥1 EDSS point (if at randomization EDSS ≤ 5.0) or 0.5 EDSS point (if at randomization EDSS ≥ 5.5) in the last 12 months ii. ≥1 clinically documented relapse or ≥ 1 GEL at MRI within the last twelve months.\n\nc. Primary progressive MS (PPMS) patients with all the following features: i. an increase of ≥1 EDSS point (if at randomization EDSS ≤ 5.0) or 0.5 EDSS point (if at randomization EDSS ≥5.5), in the last twelve months ii. ≥ 1 GEL at MRI performed within the last 12 months iii. positive cerebrospinal fluid (CSF) (oligoclonal banding)\n\nAge 18 to 50 years\nDisease duration 2 to 10 years (included)\nEDSS 3.0 to 6.5\n\nExclusion Criteria:\n\nRRMS not fulfilling inclusion criteria\nSPMS not fulfilling inclusion criteria\nPPMS not fulfilling inclusion criteria\nAny active or chronic infection including infection with HIV1-2 or chronic Hepatitis B or Hepatitis C\nTreatment with any immunosuppressive therapy, including natalizumab and fingolimod, within the 3 months prior to randomization\nTreatment with interferon-beta or glatiramer acetate within the 30 days prior to randomization\nTreatment with corticosteroids within the 30 days prior to randomization\nRelapse occurred during the 60 days prior to randomization\nPrevious history of a malignancy other than basal cell carcinoma of the skin or carcinoma in situ that has been in remission for more than one year\nSeverely limited life expectancy by another co-morbid illness\nHistory of previous diagnosis of myelodysplasia or previous hematologic disease or current clinically relevant abnormalities of white blood cell counts\nPregnancy or risk or pregnancy (this includes patients that are unwilling to practice active contraception during the duration of the study)\neGFR < 60 mL/min/1.73m2 or known renal failure or inability to undergo MRI examination.\nInability to give written informed consent in accordance with research ethics board guidelines",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "50 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Lou Brundin, MD.Professor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+46 7074848505",
            "CentralContactPhoneExt": "+46",
            "CentralContactEMail": "lou.brundin@karolinska.se"
          },
          {
            "CentralContactName": "Ellen Iacobaeus, MD.PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+46 707433644",
            "CentralContactPhoneExt": "+46",
            "CentralContactEMail": "ellen.iacobaeus@karolinska.se"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Karolinska Institute, Karolinska University Hospital Solna",
            "LocationStatus": "Recruiting",
            "LocationCity": "Stockholm",
            "LocationZip": "171 76",
            "LocationCountry": "Sweden",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Lou Brundin, MD. Professor",
                  "LocationContactRole": "Principal Investigator"
                },
                {
                  "LocationContactName": "Ellen Iacobaeus, MD. PhD",
                  "LocationContactRole": "Sub-Investigator"
                },
                {
                  "LocationContactName": "Katarina Le Blanc, MD. Professor",
                  "LocationContactRole": "Sub-Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "31072380",
            "ReferenceType": "derived",
            "ReferenceCitation": "Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009103",
            "ConditionMeshTerm": "Multiple Sclerosis"
          },
          {
            "ConditionMeshId": "D000012598",
            "ConditionMeshTerm": "Sclerosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000020278",
            "ConditionAncestorTerm": "Demyelinating Autoimmune Diseases, CNS"
          },
          {
            "ConditionAncestorId": "D000020274",
            "ConditionAncestorTerm": "Autoimmune Diseases of the Nervous System"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000003711",
            "ConditionAncestorTerm": "Demyelinating Diseases"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11212",
            "ConditionBrowseLeafName": "Multiple Sclerosis",
            "ConditionBrowseLeafAsFound": "Multiple Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14567",
            "ConditionBrowseLeafName": "Sclerosis",
            "ConditionBrowseLeafAsFound": "Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21251",
            "ConditionBrowseLeafName": "Demyelinating Autoimmune Diseases, CNS",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21247",
            "ConditionBrowseLeafName": "Autoimmune Diseases of the Nervous System",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6061",
            "ConditionBrowseLeafName": "Demyelinating Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    }
  }
}